Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Experts Share What They're Going to Work on Improving in Practice This Year

February 1st 2020

OncLive interviewed experts at the State of the Science Summits™ in January 2020 on what they are going to work on improving in clinical practice this year.

Dr. Liebman on Toxicities of BRAF Inhibitors in Melanoma

January 31st 2020

Tracey Liebman, MD, discusses the toxicities associated with BRAF inhibitors in melanoma.

Investigators Tackle Resistance, Poor Response in Metastatic Melanoma

January 31st 2020

Immune checkpoint inhibitors (ICIs) combined with the anti–CTLA-4 agent ipilimumab (Yervoy) have dramatically improved survival in metastatic melanoma, but resistance and lack of response remain obstacles to wider efficacy, Mario Sznol, MD, said in a presentation during the 4th Annual International Congress on Immunotherapies in Cancer®. Multiple efforts are under way to understand these issues better and develop improved biomarkers for response, Sznol added.

Surgical Resection Now Individualized Approach in Modern Melanoma Paradigm

January 28th 2020

Richard L. Shapiro, MD, discusses the evolution and current role of surgery in advanced melanoma.

Dr. Weber on Adjuvant Approaches in Stage III Melanoma

January 27th 2020

Jeffrey S. Weber, MD, PhD, discusses adjuvant approaches in stage III melanoma.

Dr. Pavlick on Importance of Immunotherapy in Metastatic Melanoma

January 27th 2020

Anna C. Pavlick, DO, discusses the importance of immunotherapy for patients with metastatic melanoma.

Treatment-Related Dermatologic AEs in Melanoma Require Careful Management

January 24th 2020

Tracey Liebman, MD, discusses the identification and management of treatment-related dermatologic AEs in patients with melanoma.

Targeting the Hedgehog Pathway Holds Promises and Pitfalls

January 18th 2020

Although small molecule inhibitors of the Hedgehog signaling pathway have transformed the treatment paradigm for advanced basal cell carcinoma, the most common form of skin cancer, efforts to expand their use to other tumor types have proved elusive.

Optimal AE Management Required With Immunotherapy in Melanoma

January 17th 2020

Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses optimal management of adverse events associated with various therapies for patients with melanoma.

Guiding Treatment Decisions in Newly Diagnosed Metastatic Melanoma

January 16th 2020

Anna C. Pavlick, DO, discusses key trials that have shed light on how to best treat patients with newly diagnosed, metastatic melanoma.

Biomarker Hunt Finds Potential With ctDNA in Melanoma

January 16th 2020

David Polsky, MD, PhD, discusses the development and clinical utility of biomarkers in melanoma.

Adjuvant Therapy Transforms Treatment in Advanced Melanoma

January 16th 2020

Jeffrey S. Weber, MD, PhD, discusses the activity of targeted therapy in metastatic melanoma, its adoption into the adjuvant setting, and the optimal use of immunotherapy in the space.

SITC Poised to Expand Toolkit of Immunotherapy Guidelines

January 11th 2020

The Society for Immunotherapy of Cancer is developing a growing menu of guidelines with treatment algorithms for specific cancer types to help practicing oncologists navigate the appropriate use of this emerging modality.

Dr. Sznol on Immune-Related Toxicities in Melanoma

January 11th 2020

Mario Sznol, MD, discusses the adverse events that can occur from nivolumab in combination with ipilimumab for patients with melanoma.

Dr. Luke on Current and Emerging Treatment Approaches in Metastatic Melanoma

January 7th 2020

Jason J. Luke, MD, FACP, discusses current and emerging treatment paradigms in metastatic melanoma.

Dr. Sznol on Managing Patients Beyond Initial Treatment in Melanoma

January 3rd 2020

Mario Sznol, MD, discusses the management of patients with melanoma who progress on immune checkpoint inhibitors.

Dr. McQuade on Age as a Predictor of Response to Neoadjuvant Immunotherapy in Melanoma

December 14th 2019

Jennifer McQuade, MD, MS, MA, LAc, discusses how age may serve as a predictor of response to neoadjuvant immunotherapy for patients with melanoma.

Atezolizumab Plus Cobimetinib/Vemurafenib Meets PFS Endpoint in Frontline BRAF V600+ Advanced Melanoma

December 13th 2019

The triplet regimen of atezolizumab, cobimetinib, and vemurafenib was found to improve progression-free survival compared with cobimetinib/vemurafenib plus placebo in patients with previously untreated BRAF V600 mutation–positive advanced melanoma.

Dr. Marron on Shortening Treatment Duration of Immunotherapy in Melanoma

December 12th 2019

Thomas Marron, MD, PhD, discusses the potential benefit of shortening the length of immunotherapy treatment in melanoma.

The New Horizon in Melanoma

December 11th 2019

Jeffrey S. Weber, MD, PhD, looks to earlier use of immunotherapy and novel combinations in melanoma.